RBC Capital Lifts Insulet (PODD) PT to $365 on Strong Momentum, Q3 Guidance Optimism

Insulet Corporation (NASDAQ:PODD) is one of the best NASDAQ growth stocks to buy for the next 5 years. On October 10, RBC Capital raised the price target on Insulet to $365 from $350 and kept an Outperform rating on the shares as part of a broader research note on the MedTech sector ahead of Q3 2025 results due to attractive valuations and numerous opportunities in the Medical Supplies & Devices sector.

RBC Capital is particularly bullish on Insulet. Investor sentiment is positive ahead of the company’s Q3 earnings report because management has already signaled that strong business momentum will allow them to surpass their official Q3 guidance, which essentially minimizes the risk for the quarter.

Additionally, on October 21, Stifel resumed coverage on several MedTech companies with an upbeat outlook driven by the steady adoption of continuous glucose monitors and insulin pumps. In the Insulin Pump segment, Stifel suggested that the Type 2 Insulin-intensive opportunity is significant for pump providers, which, according to the firm, adds to Insulet’s strengths.

Insulet Corporation (NASDAQ:PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the US and internationally.

While we acknowledge the potential of PODD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.